Rupert Wolfgang Strauss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rupert Wolfgang Strauss has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Andreas Wedrich
Department of Ophthalmology, Medical University Graz, Graz, Austria
5 shared publicationsElena Moser
Department of Ophthalmology, Medical University Graz, Graz, Austria
3 shared publicationsLaura Posch-Pertl
Department of Ophthalmology, Medical University Graz, Graz, Austria
3 shared publicationsMarina Casazza
Department of Ophthalmology, Medical University Graz, Graz, Austria
3 shared publicationsCarmen Perales
Department of Ophthalmology, Medical University Graz, Graz, Austria
2 shared publicationsGernot Schließleder
Med Univ Graz, Dept Ophthalmol, Graz, Austria
2 shared publications
Latest Publications
- 5 October 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 143-144
Retinale Dystrophien – ein Ausblick in die Zukunft
- 5 October 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 143-144
Retinale Dystrophien – ein Ausblick in die Zukunft
- Open Access
- 23 September 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 163-175
Stargardt disease: clinical studies over the past 5 years—a systematic review
Summary: Background: Stargardt disease type 1 (STGD1) is the most common juvenile macular degeneration and one of the leading causes of visual impairment and blindness among children and working adults across Europe. There are currently no approved therapies for STGD1, but several therapeutic approaches including pharmacotherapy, gene therapy, neuroprotection, and stem cell therapy are under investigation in clinical studies and trials. Here, we review the current status of evolving therapies for STDG1. Methods: This systematic review is based on the PRISMA‑P checklist using various scientific databases. Only case series and (non-)randomized clinical studies were included, with preclinical and basic science studies excluded. All included studies were individually assessed using the ROBINS‑I Tool of the Cochrane Collaboration and the TREND-Checklist for BIAS assessment. Results: From the initial search, 314 records were identified, including 72 from PubMed, 96 from Embase, 41 from the Cochrane Library, 68 from Google Scholar, and 37 from Epistemonikos. After removing duplicates, the titles, abstracts, and full texts were screened according to predefined PICO criteria: population with genetically and clinically confirmed STDG1, interventions such as gene therapy, pharmacological approaches, stem cell therapy, and neuroprotection; comparison groups appropriate to the study design, such as placebo, the fellow eye, natural progression, or historical cohorts; and outcomes , including structural progression (assessed by fundus autofluorescence and optical coherence tomography), functional outcomes, and safety. Six studies met these criteria and were included. Of these, one investigated the gene therapy SAR422459, one evaluated the pharmacological agent emixustat, three assessed stem cell-based retinal pigment epithelium transplantation, and one examined neuroprotection through saffron supplementation. Conclusion: Although STGD1 remains a challenging condition, new therapies in this review have shown potential in clinical trials. Ongoing methods aim to optimize the use of stem cell-based retinal pigment epithelium cells, refine delivery methods for the large ABCA4 gene, and explore genome editing techniques, such as CRISPR, to correct ABCA4 mutations, even though challenges such as off-target effects and DNA repair errors remain. Pharmacological approaches are focused on optimizing dosing for safety and efficacy. With further research on larger cohorts and long-term evaluation, there is hope for effective therapies.
- 23 September 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 163-175
Open AccessStargardt disease: clinical studies over the past 5 years—a systematic review
Summary: Background: Stargardt disease type 1 (STGD1) is the most common juvenile macular degeneration and one of the leading causes of visual impairment and blindness among children and working adults across Europe. There are currently no approved therapies for STGD1, but several therapeutic approaches including pharmacotherapy, gene therapy, neuroprotection, and stem cell therapy are under investigation in clinical studies and trials. Here, we review the current status of evolving therapies for STDG1. Methods: This systematic review is based on the PRISMA‑P checklist using various scientific databases. Only case series and (non-)randomized clinical studies were included, with preclinical and basic science studies excluded. All included studies were individually assessed using the ROBINS‑I Tool of the Cochrane Collaboration and the TREND-Checklist for BIAS assessment. Results: From the initial search, 314 records were identified, including 72 from PubMed, 96 from Embase, 41 from the Cochrane Library, 68 from Google Scholar, and 37 from Epistemonikos. After removing duplicates, the titles, abstracts, and full texts were screened according to predefined PICO criteria: population with genetically and clinically confirmed STDG1, interventions such as gene therapy, pharmacological approaches, stem cell therapy, and neuroprotection; comparison groups appropriate to the study design, such as placebo, the fellow eye, natural progression, or historical cohorts; and outcomes , including structural progression (assessed by fundus autofluorescence and optical coherence tomography), functional outcomes, and safety. Six studies met these criteria and were included. Of these, one investigated the gene therapy SAR422459, one evaluated the pharmacological agent emixustat, three assessed stem cell-based retinal pigment epithelium transplantation, and one examined neuroprotection through saffron supplementation. Conclusion: Although STGD1 remains a challenging condition, new therapies in this review have shown potential in clinical trials. Ongoing methods aim to optimize the use of stem cell-based retinal pigment epithelium cells, refine delivery methods for the large ABCA4 gene, and explore genome editing techniques, such as CRISPR, to correct ABCA4 mutations, even though challenges such as off-target effects and DNA repair errors remain. Pharmacological approaches are focused on optimizing dosing for safety and efficacy. With further research on larger cohorts and long-term evaluation, there is hope for effective therapies.
- Open Access
- 7 September 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 176-190
Retinitis pigmentosa: klinische Studien der letzten 5 Jahre – eine systematische Literaturrecherche
Zusammenfassung: Hintergrund: Retinitis pigmentosa (RP) ist mit einer Prävalenz von etwa 1: 4000 die häufigste Form der erblichen Netzhauterkrankungen weltweit. Erbliche Netzhauterkrankungen sind die führende Ursache für Sehbehinderung und Erblindung im Kindes-, Jugend- und erwerbsfähigen Alter in Österreich. Derzeit ist mit Voretigene neparvovec die einzige zugelassene Gentherapie für eine Unterform der RPE65 -assoziierten Retinopathie verfügbar, während Gentherapie, Pharmakotherapie, Neuroprotektion und Stammzelltherapie intensiv klinisch erforscht werden. Material und Methoden: Die systematische Literaturrecherche erfolgte nach den PRISMA-P-Kriterien, die eine standardisierte und transparente Methodik gewährleisten. Klinische Studien zur Therapie der Retinitis pigmentosa aus dem Zeitraum von 2019 bis August 2025 wurden hinsichtlich Wirksamkeit und Sicherheit der jeweiligen Therapieansätze systematisch analysiert, wobei die ROBINS-I-Kriterien Anwendung fanden. Ergebnisse: Von 4004 identifizierten Publikationen wurden 22 eingeschlossen: 5 zur Gentherapie, 6 zur Pharmakotherapie, 6 zur Neuroprotektion und 5 zur Stammzelltherapie. Die Studien zur Gentherapie zeigten funktionelle Verbesserungen bei insgesamt guter Sicherheit. Sowohl pharmakologische als auch neuroprotektive Ansätze bewahrten funktionelle und strukturelle Stabilität, während stammzellbasierte Verfahren teilweise eine verbesserte Sehschärfe und makuläre Sensitivität erreichten. Schlussfolgerungen: Gen- und stammzellbasierte Therapien zeigen vielversprechende Resultate, deren Langzeitsicherheit und Wirksamkeit jedoch noch bestätigt werden müssen. Neuroprotektive und pharmakologische Strategien bleiben aufgrund ihrer breiten Verfügbarkeit eine genunabhängige Behandlungsoption. Es sind größere, kontrollierte Studien notwendig, um die langfristigen Effekte und die klinische Bedeutung dieser Therapieansätze zu ermitteln.
- 7 September 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 176-190
Open AccessRetinitis pigmentosa: klinische Studien der letzten 5 Jahre – eine systematische Literaturrecherche
Zusammenfassung: Hintergrund: Retinitis pigmentosa (RP) ist mit einer Prävalenz von etwa 1: 4000 die häufigste Form der erblichen Netzhauterkrankungen weltweit. Erbliche Netzhauterkrankungen sind die führende Ursache für Sehbehinderung und Erblindung im Kindes-, Jugend- und erwerbsfähigen Alter in Österreich. Derzeit ist mit Voretigene neparvovec die einzige zugelassene Gentherapie für eine Unterform der RPE65 -assoziierten Retinopathie verfügbar, während Gentherapie, Pharmakotherapie, Neuroprotektion und Stammzelltherapie intensiv klinisch erforscht werden. Material und Methoden: Die systematische Literaturrecherche erfolgte nach den PRISMA-P-Kriterien, die eine standardisierte und transparente Methodik gewährleisten. Klinische Studien zur Therapie der Retinitis pigmentosa aus dem Zeitraum von 2019 bis August 2025 wurden hinsichtlich Wirksamkeit und Sicherheit der jeweiligen Therapieansätze systematisch analysiert, wobei die ROBINS-I-Kriterien Anwendung fanden. Ergebnisse: Von 4004 identifizierten Publikationen wurden 22 eingeschlossen: 5 zur Gentherapie, 6 zur Pharmakotherapie, 6 zur Neuroprotektion und 5 zur Stammzelltherapie. Die Studien zur Gentherapie zeigten funktionelle Verbesserungen bei insgesamt guter Sicherheit. Sowohl pharmakologische als auch neuroprotektive Ansätze bewahrten funktionelle und strukturelle Stabilität, während stammzellbasierte Verfahren teilweise eine verbesserte Sehschärfe und makuläre Sensitivität erreichten. Schlussfolgerungen: Gen- und stammzellbasierte Therapien zeigen vielversprechende Resultate, deren Langzeitsicherheit und Wirksamkeit jedoch noch bestätigt werden müssen. Neuroprotektive und pharmakologische Strategien bleiben aufgrund ihrer breiten Verfügbarkeit eine genunabhängige Behandlungsoption. Es sind größere, kontrollierte Studien notwendig, um die langfristigen Effekte und die klinische Bedeutung dieser Therapieansätze zu ermitteln.
- Open Access
- 22 April 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 1-10
Approved retinal prostheses: comparison, current knowledge, and developments—a systematic review
Summary: Background: Recent epidemiological research showed that inherited retinal dystrophies are the leading cause of severe visual impairment among children and working adults across Europe, notably in Austria. Currently, available treatments are primarily supportive with limitations. However, promising new therapeutic approaches such as retinal prostheses offer prospects for addressing these challenges. Approved retinal prostheses are currently restricted to epiretinal and subretinal implants. Here, we analyze and compared the medical risks and subretinal enhancements in visual function of both systems considering their respective rehabilitative differences. Furthermore, we explore the current state of knowledge and future developments of retinal prostheses. Material and methods: This systematic review is based on PRISMA‑P using diverse scientific databases. Only non-randomized clinical studies and case series were included. All included studies were individually assessed with the ROBINS‑I tool of the Cochrane Collaboration and the TREND checklist for bias assessment. Results: Out of 564 screened records, 16 non-randomized controlled clinical studies were included, comprising eight on subretinal implants and eight on epiretinal implants. Data analysis revealed that epiretinal implants provided more consistent outcomes in motion detection and object localization, while subretinal implants showed greater variability with occasional superior gains in visual acuity but at the cost of higher complication rates. The overall bias risk was moderate. Conclusion: Both prosthesis systems can restore basic visual functions but differ in consistency, safety profile, and methodological rigor. Further standardized, long-term studies are needed to enable reliable comparisons and optimize patient outcomes. A glimpse into the future promises many new therapeutic approaches, such as artificial intelligence-supported retinal prostheses.
- 22 April 2026
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 40 (5) , 1-10
Open AccessApproved retinal prostheses: comparison, current knowledge, and developments—a systematic review
Summary: Background: Recent epidemiological research showed that inherited retinal dystrophies are the leading cause of severe visual impairment among children and working adults across Europe, notably in Austria. Currently, available treatments are primarily supportive with limitations. However, promising new therapeutic approaches such as retinal prostheses offer prospects for addressing these challenges. Approved retinal prostheses are currently restricted to epiretinal and subretinal implants. Here, we analyze and compared the medical risks and subretinal enhancements in visual function of both systems considering their respective rehabilitative differences. Furthermore, we explore the current state of knowledge and future developments of retinal prostheses. Material and methods: This systematic review is based on PRISMA‑P using diverse scientific databases. Only non-randomized clinical studies and case series were included. All included studies were individually assessed with the ROBINS‑I tool of the Cochrane Collaboration and the TREND checklist for bias assessment. Results: Out of 564 screened records, 16 non-randomized controlled clinical studies were included, comprising eight on subretinal implants and eight on epiretinal implants. Data analysis revealed that epiretinal implants provided more consistent outcomes in motion detection and object localization, while subretinal implants showed greater variability with occasional superior gains in visual acuity but at the cost of higher complication rates. The overall bias risk was moderate. Conclusion: Both prosthesis systems can restore basic visual functions but differ in consistency, safety profile, and methodological rigor. Further standardized, long-term studies are needed to enable reliable comparisons and optimize patient outcomes. A glimpse into the future promises many new therapeutic approaches, such as artificial intelligence-supported retinal prostheses.
- Open Access
- 18 July 2024
- Published by S. Karger AG in Ophthalmic Research
- Vol. 67 (1) , 435-447
The Progression of Stargardt Disease (ProgStar) as determined by spectral-domain optical coherence tomography over a 24-month period (ProgStar Report No. 19)
Introduction: To evaluate the progression of atrophy as determined by spectral-domain optical coherence tomography (SD-OCT) in patients with molecularly confirmed ABCA4-associated Stargardt disease type 1 (STGD1) over a 24-month period in a multicenter prospective cohort study. Methods: SD-OCT images from 428 eyes of 236 patients were analyzed. Change of mean thickness (MT) and intact area were estimated after semi-automated segmentation for the following individual layers in the central subfield (CS), inner ring (IR) and outer ring (OR) of the ETDRS grid: retinal pigment epithelium (RPE), outer segments (OS), inner segments (IS), outer nuclear layer (ONL) inner retina (IR) and total retina (TR). Results: Statistically significant decreases of all outer retinal layers (RPE, OS, IS, and ONL) could be observed over a 24-month period both in decline of mean retinal thickness and intact area (p<.0001, respectively); whereas the inner retina showed an increase of retinal thickness in the central subfield and inner ring and remained unchanged in the outer ring. Conclusions: Significant loss could be detected in outer retinal layers by SD-OCT over a 24-month period in patients with STGD1. Loss of thickness and/or intact area of such layers may serve as potential endpoints for clinical trials that aim to slow down the disease progression of STGD1.
- 18 July 2024
- Published by S. Karger AG in Ophthalmic Research
- Vol. 67 (1) , 435-447
Open AccessThe Progression of Stargardt Disease (ProgStar) as determined by spectral-domain optical coherence tomography over a 24-month period (ProgStar Report No. 19)
Introduction: To evaluate the progression of atrophy as determined by spectral-domain optical coherence tomography (SD-OCT) in patients with molecularly confirmed ABCA4-associated Stargardt disease type 1 (STGD1) over a 24-month period in a multicenter prospective cohort study. Methods: SD-OCT images from 428 eyes of 236 patients were analyzed. Change of mean thickness (MT) and intact area were estimated after semi-automated segmentation for the following individual layers in the central subfield (CS), inner ring (IR) and outer ring (OR) of the ETDRS grid: retinal pigment epithelium (RPE), outer segments (OS), inner segments (IS), outer nuclear layer (ONL) inner retina (IR) and total retina (TR). Results: Statistically significant decreases of all outer retinal layers (RPE, OS, IS, and ONL) could be observed over a 24-month period both in decline of mean retinal thickness and intact area (p<.0001, respectively); whereas the inner retina showed an increase of retinal thickness in the central subfield and inner ring and remained unchanged in the outer ring. Conclusions: Significant loss could be detected in outer retinal layers by SD-OCT over a 24-month period in patients with STGD1. Loss of thickness and/or intact area of such layers may serve as potential endpoints for clinical trials that aim to slow down the disease progression of STGD1.
- Open Access
- 27 February 2024
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 38 (5) , 191-208
Juvenile Uveitis
Zusammenfassung: Etwa 5–10 % aller Uveitisfälle treten bei Kindern auf. Die Erkrankung verläuft oft ohne Symptome, was zu einer verzögerten Diagnose und möglichen Schäden an den Augen führen kann. Infektiöse und nichtinfektiöse Ursachen können zur Uveitis führen, wobei die juvenile idiopathische Arthritis die häufigste Ursache bei Kindern und Jugendlichen ist. Die Behandlung hängt von der Ursache ab und kann eine Immunsuppression beinhalten. Katarakt, Glaukom und Amblyopie sind die häufigsten Komplikationen, die das Sehvermögen beeinträchtigen können. Regelmäßige Kontrollen sind auch nach Inaktivität der Uveitis wichtig, um erneute Entzündungsschübe frühzeitig zu erkennen und die Therapie anzupassen. Das Ziel dieser Arbeit ist es, einen Überblick über das klinische Erscheinungsbild, potenzielle Ursachen, Therapiemöglichkeiten und Komplikationen der Uveitis bei Kindern zu geben.
- 27 February 2024
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 38 (5) , 191-208
Open AccessJuvenile Uveitis
Zusammenfassung: Etwa 5–10 % aller Uveitisfälle treten bei Kindern auf. Die Erkrankung verläuft oft ohne Symptome, was zu einer verzögerten Diagnose und möglichen Schäden an den Augen führen kann. Infektiöse und nichtinfektiöse Ursachen können zur Uveitis führen, wobei die juvenile idiopathische Arthritis die häufigste Ursache bei Kindern und Jugendlichen ist. Die Behandlung hängt von der Ursache ab und kann eine Immunsuppression beinhalten. Katarakt, Glaukom und Amblyopie sind die häufigsten Komplikationen, die das Sehvermögen beeinträchtigen können. Regelmäßige Kontrollen sind auch nach Inaktivität der Uveitis wichtig, um erneute Entzündungsschübe frühzeitig zu erkennen und die Therapie anzupassen. Das Ziel dieser Arbeit ist es, einen Überblick über das klinische Erscheinungsbild, potenzielle Ursachen, Therapiemöglichkeiten und Komplikationen der Uveitis bei Kindern zu geben.
- Open Access
- 17 November 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 259, 109-116
Progression of PROM1-Associated Retinal Degeneration as Determined by Spectral-Domain Optical Coherence Tomography Over a 24-Month Period
- 17 November 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 259, 109-116
Open AccessProgression of PROM1-Associated Retinal Degeneration as Determined by Spectral-Domain Optical Coherence Tomography Over a 24-Month Period
- 20 April 2023
- Published by BMJ in British Journal of Ophthalmology
- Vol. 108 (4) , 558-565
Deep phenotyping of PROM1-associated retinal degeneration
Background/aims: The purpose of this study was to investigate retinal structure in detail of subjects with autosomal-dominant (AD) and autosomal-recessive (AR)PROM1-associated retinal degeneration (PROM1-RD), study design: institutional, cross-sectional study.Methods: Four eyes from four subjects (three with AD and one with AR)PROM1-RD were investigated by ophthalmic examination including best-corrected visual acuity (BCVA) and multimodal retinal imaging: fundus autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT) and adaptive optics scanning light ophthalmoscopy. Quantitative assessment of atrophic lesions determined by FAF, thickness of individual retinal layers and cone photoreceptor quantification was performed.Results: BCVA ranged from 20/16 to 20/200. Initial pathological changes included the presence of hyperautofluorescent spots on FAF imaging, while later stages demonstrated discrete areas of atrophy. In all patients, thinning of the outer retinal layers on SD-OCT with varying degrees of atrophy could be detected depending on disease-causing variants and age. Cone density was quantified both in central and/or at different eccentricities from the fovea. Longitudinal assessments were possible in two patients.Conclusions: PROM1-RD comprises a wide range of clinical phenotypes. Depending on the stage of disease, the cone mosaic inPROM1-RD is relatively preserved and can potentially be targeted by cone-directed interventions.
- 20 April 2023
- Published by BMJ in British Journal of Ophthalmology
- Vol. 108 (4) , 558-565
Deep phenotyping of PROM1-associated retinal degeneration
Background/aims: The purpose of this study was to investigate retinal structure in detail of subjects with autosomal-dominant (AD) and autosomal-recessive (AR)PROM1-associated retinal degeneration (PROM1-RD), study design: institutional, cross-sectional study.Methods: Four eyes from four subjects (three with AD and one with AR)PROM1-RD were investigated by ophthalmic examination including best-corrected visual acuity (BCVA) and multimodal retinal imaging: fundus autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT) and adaptive optics scanning light ophthalmoscopy. Quantitative assessment of atrophic lesions determined by FAF, thickness of individual retinal layers and cone photoreceptor quantification was performed.Results: BCVA ranged from 20/16 to 20/200. Initial pathological changes included the presence of hyperautofluorescent spots on FAF imaging, while later stages demonstrated discrete areas of atrophy. In all patients, thinning of the outer retinal layers on SD-OCT with varying degrees of atrophy could be detected depending on disease-causing variants and age. Cone density was quantified both in central and/or at different eccentricities from the fovea. Longitudinal assessments were possible in two patients.Conclusions: PROM1-RD comprises a wide range of clinical phenotypes. Depending on the stage of disease, the cone mosaic inPROM1-RD is relatively preserved and can potentially be targeted by cone-directed interventions.
- Open Access
- 10 January 2023
- Published by Wiley in Journal of Ophthalmology
- Vol. 2023 (1) , 3165965
Evaluating the Treatment of Diabetic Macular Edema with Aflibercept Based on a Regional Network of Ophthalmologic Care Givers
Purpose. In Austria, anti‐VEGF therapies are reimbursed only in clinical settings. This study aimed to describe the outcome of a treat and extend regimen (TER) with aflibercept for diabetic macular edema (DME) in a network of practitioners. Methods. In a prospective study over 36 months, patients with DME were treated with a loading dose of aflibercept and further on with adjusted treatment intervals based on optical coherence tomography (OCT) findings. All patients were monitored in an outpatient setting by regional ophthalmologists, and the treatment was administered in the clinic. Main outcome parameters were best‐corrected visual acuity (BCVA) from baseline to the last regular visit. Number of visits at the practitioner’s office as well as the number of injections were secondary outcome parameters. Results. Thirty‐three patients completed the study at their final visit. BCVA improved significantly by 5.8 letters between baseline and the final visit from 70.4 letters at baseline (p = 0.004). Patients visited the practitioner’s office 12.8 times in the observation period of 36 months. 3.7, 5.1, and 3.9 visits were performed, respectively, in the first, second, and third years, and 25.5 ± 7.9 injections were performed. The mean interval of injections over the observation period was 6.2 ± 2.2 in weeks. Conclusion. The treat and extend regimen was valuable for treating patients with DME in this specific setting. The functional results of this study were comparable to those of other real‐world evaluations. Adherence to the same treating institution seems to be important to avoid differences in therapeutic decision making and may also increase patient’s compliance.
- 10 January 2023
- Published by Wiley in Journal of Ophthalmology
- Vol. 2023 (1) , 3165965
Open AccessEvaluating the Treatment of Diabetic Macular Edema with Aflibercept Based on a Regional Network of Ophthalmologic Care Givers
Purpose. In Austria, anti‐VEGF therapies are reimbursed only in clinical settings. This study aimed to describe the outcome of a treat and extend regimen (TER) with aflibercept for diabetic macular edema (DME) in a network of practitioners. Methods. In a prospective study over 36 months, patients with DME were treated with a loading dose of aflibercept and further on with adjusted treatment intervals based on optical coherence tomography (OCT) findings. All patients were monitored in an outpatient setting by regional ophthalmologists, and the treatment was administered in the clinic. Main outcome parameters were best‐corrected visual acuity (BCVA) from baseline to the last regular visit. Number of visits at the practitioner’s office as well as the number of injections were secondary outcome parameters. Results. Thirty‐three patients completed the study at their final visit. BCVA improved significantly by 5.8 letters between baseline and the final visit from 70.4 letters at baseline (p = 0.004). Patients visited the practitioner’s office 12.8 times in the observation period of 36 months. 3.7, 5.1, and 3.9 visits were performed, respectively, in the first, second, and third years, and 25.5 ± 7.9 injections were performed. The mean interval of injections over the observation period was 6.2 ± 2.2 in weeks. Conclusion. The treat and extend regimen was valuable for treating patients with DME in this specific setting. The functional results of this study were comparable to those of other real‐world evaluations. Adherence to the same treating institution seems to be important to avoid differences in therapeutic decision making and may also increase patient’s compliance.
- Open Access
- 13 January 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0261897
Blindness and visual impairment in Central Europe
Purpose: To assess the prevalence and causes of visual impairment and blindness in a Central European country. The findings may have implications for the planning of further research and development of therapies in order to prevent blindness. Setting: Department of Ophthalmology, Medical University of Graz, Austria. Design: Retrospective, epidemiological study. Methods: The database of the Main Confederation of Austrian Social Insurances was searched for patients with visual impairment, legal blindness or deaf-blindness. This database gathers data from patients of all insurance providers in the country who receive care due to visual impairment and blindness. To determine the prevalence of these conditions, the number of all entries recorded in February 2019 was evaluated. Additionally, all new entries between (January 1st,) 2017, and (December 31st,) 2018, were analysed for distinct characteristics, such as sex, the cause of blindness/visual impairment, and age. Since health care allowances can provide a considerable source of income (459.90€-936.90€ per month), good coverage of practically all patients who are blind and visually impaired in the country can be assumed. Results: On February 2nd, 2019, 17,730 patients with visual impairments, blindness or deaf-blindness were registered in Austria, resulting in a prevalence of these diagnoses of 0.2% in the country. During the observational period from 2017 to 2018, 4040 persons met the inclusion criteria. Of these, 2877 were female (65.3%), and 1527 were male (34.7%). The mean age was 75.7 ± 18.0 years (median 82). Most patients (n = 3675, 83.4%) were of retirement age, while 729 (16.6%) were working-age adults or minors. In total, an incidence of 25.0 (95% confidence limit (CL) 24.3–25.8) per 100,000 person-years was observed from 2017 to 2018. A higher incidence was observed for females (32.2, 95% CL 31.0–33.3) than for males (17.7, 95% CL 16.8–18.5). Incidences where higher for males in lower age groups (e.g. 10–14 years: rate ratio RR = 2.7, 95% CL 1.1–6.8), and higher for females in higher age groups (e.g. 70–74 years: RR = 0.6, 95% CL 0.5–0.8). In total, the most frequent diagnoses were macular degeneration (1075 persons, 24.4%), other retinal disorders (493 persons, 11.2%) and inherited retinal and choroidal diseases (IRDs) (186 persons, 4.2%). Persons with IRDs were significantly younger compared to persons with macular degeneration or retinal disorders (IRDs: median 57, range 2–96 vs 83, 5–98 and 82, 1–98 years, p<0.001). For persons of retirement age, macular degeneration, other retinal disorders and glaucoma were the three most frequent diagnoses. In contrast, among working-aged adults and children, IRDs were the leading cause of visual impairment and blindness (103 persons, 14.1%). Conclusion: These data show that IRDs are the leading cause of blindness and visual impairment in working-aged persons and children in Austria. Thus, these findings suggest to draw attention to enhance further research in the fields of emerging therapies for IRDs.
- 13 January 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0261897
Open AccessBlindness and visual impairment in Central Europe
Purpose: To assess the prevalence and causes of visual impairment and blindness in a Central European country. The findings may have implications for the planning of further research and development of therapies in order to prevent blindness. Setting: Department of Ophthalmology, Medical University of Graz, Austria. Design: Retrospective, epidemiological study. Methods: The database of the Main Confederation of Austrian Social Insurances was searched for patients with visual impairment, legal blindness or deaf-blindness. This database gathers data from patients of all insurance providers in the country who receive care due to visual impairment and blindness. To determine the prevalence of these conditions, the number of all entries recorded in February 2019 was evaluated. Additionally, all new entries between (January 1st,) 2017, and (December 31st,) 2018, were analysed for distinct characteristics, such as sex, the cause of blindness/visual impairment, and age. Since health care allowances can provide a considerable source of income (459.90€-936.90€ per month), good coverage of practically all patients who are blind and visually impaired in the country can be assumed. Results: On February 2nd, 2019, 17,730 patients with visual impairments, blindness or deaf-blindness were registered in Austria, resulting in a prevalence of these diagnoses of 0.2% in the country. During the observational period from 2017 to 2018, 4040 persons met the inclusion criteria. Of these, 2877 were female (65.3%), and 1527 were male (34.7%). The mean age was 75.7 ± 18.0 years (median 82). Most patients (n = 3675, 83.4%) were of retirement age, while 729 (16.6%) were working-age adults or minors. In total, an incidence of 25.0 (95% confidence limit (CL) 24.3–25.8) per 100,000 person-years was observed from 2017 to 2018. A higher incidence was observed for females (32.2, 95% CL 31.0–33.3) than for males (17.7, 95% CL 16.8–18.5). Incidences where higher for males in lower age groups (e.g. 10–14 years: rate ratio RR = 2.7, 95% CL 1.1–6.8), and higher for females in higher age groups (e.g. 70–74 years: RR = 0.6, 95% CL 0.5–0.8). In total, the most frequent diagnoses were macular degeneration (1075 persons, 24.4%), other retinal disorders (493 persons, 11.2%) and inherited retinal and choroidal diseases (IRDs) (186 persons, 4.2%). Persons with IRDs were significantly younger compared to persons with macular degeneration or retinal disorders (IRDs: median 57, range 2–96 vs 83, 5–98 and 82, 1–98 years, p<0.001). For persons of retirement age, macular degeneration, other retinal disorders and glaucoma were the three most frequent diagnoses. In contrast, among working-aged adults and children, IRDs were the leading cause of visual impairment and blindness (103 persons, 14.1%). Conclusion: These data show that IRDs are the leading cause of blindness and visual impairment in working-aged persons and children in Austria. Thus, these findings suggest to draw attention to enhance further research in the fields of emerging therapies for IRDs.